141 related articles for article (PubMed ID: 36159851)
21. Presence of Tim3
Klapholz M; Drage MG; Srivastava A; Anderson AC
J Pathol; 2022 Jun; 257(2):186-197. PubMed ID: 35119692
[TBL] [Abstract][Full Text] [Related]
22. [Detection of LY6G6D gene exon-intron structure,].
Beliakov IS; Karakasheva TA; Mazurenko NN
Mol Biol (Mosk); 2009; 43(4):590-8. PubMed ID: 19807019
[TBL] [Abstract][Full Text] [Related]
23. Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect
Zhong L; Shi W; Gan L; Liu X; Huo Y; Wu P; Zhang Z; Wu T; Peng H; Huang Y; Zhao Y; Yuan Y; Deng Z; Tang H
Theranostics; 2021; 11(13):6393-6406. PubMed ID: 33995664
[No Abstract] [Full Text] [Related]
24. Target-dependent T-cell activation by coligation with a PSMA x CD3 diabody induces lysis of prostate cancer cells.
Bühler P; Molnar E; Dopfer EP; Wolf P; Gierschner D; Wetterauer U; Schamel WW; Elsässer-Beile U
J Immunother; 2009; 32(6):565-73. PubMed ID: 19483653
[TBL] [Abstract][Full Text] [Related]
25. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice.
Hoyle C; Bangs CD; Chang P; Kamel O; Mehta B; Negrin RS
Blood; 1998 Nov; 92(9):3318-27. PubMed ID: 9787169
[TBL] [Abstract][Full Text] [Related]
26. Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones.
Gagnon SJ; Ennis FA; Rothman AL
J Virol; 1999 May; 73(5):3623-9. PubMed ID: 10196254
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model.
Ma H; Wang H; Sové RJ; Wang J; Giragossian C; Popel AS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859743
[TBL] [Abstract][Full Text] [Related]
28. Lymphocyte antigen 6G6D-mediated modulation through p38α MAPK and DNA methylation in colorectal cancer.
Caruso FP; D'Andrea MR; Coppola L; Landriscina M; Condelli V; Cerulo L; Giordano G; Porras A; Pancione M
Cancer Cell Int; 2022 Aug; 22(1):253. PubMed ID: 35953834
[TBL] [Abstract][Full Text] [Related]
29. Nucleophosmin is recognized by a cytotoxic T cell line derived from a rectal carcinoma patient.
Swoboda RK; Somasundaram R; Caputo L; Berencsi K; von Franzke P; Taylor DD; Marincola FM; Meropol NJ; Sigurdson E; Miller E; Herlyn D
Int J Cancer; 2010 Sep; 127(5):1124-30. PubMed ID: 20027629
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.
Chou J; Voong LN; Mortales CL; Towlerton AM; Pollack SM; Chen X; Yee C; Robbins PF; Warren EH
J Immunother; 2012; 35(2):131-41. PubMed ID: 22306901
[TBL] [Abstract][Full Text] [Related]
31. CD3
Ivanova OK; Sharapova TN; Romanova EA; Soshnikova NV; Sashchenko LP; Yashin DV
J Cell Biochem; 2017 Oct; 118(10):3359-3366. PubMed ID: 28294381
[TBL] [Abstract][Full Text] [Related]
32. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
33. Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing.
Ross SL; Sherman M; McElroy PL; Lofgren JA; Moody G; Baeuerle PA; Coxon A; Arvedson T
PLoS One; 2017; 12(8):e0183390. PubMed ID: 28837681
[TBL] [Abstract][Full Text] [Related]
34. Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE), is highly active against primary uterine serous papillary carcinoma cell lines in vitro.
Bellone S; Black J; English DP; Schwab CL; Lopez S; Cocco E; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Am J Obstet Gynecol; 2016 Jan; 214(1):99.e1-8. PubMed ID: 26272866
[TBL] [Abstract][Full Text] [Related]
35. B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma.
Hua D; Sun J; Mao Y; Chen LJ; Wu YY; Zhang XG
World J Gastroenterol; 2012 Mar; 18(9):971-8. PubMed ID: 22408358
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor.
Fu M; He Q; Guo Z; Zhou X; Li H; Zhao L; Tang H; Zhou X; Zhu H; Shen G; He Y; Lei P
Front Immunol; 2019; 10():1396. PubMed ID: 31293575
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors.
Rodolfo M; Castelli C; Bassi C; Accornero P; Sensi M; Parmiani G
Int J Cancer; 1994 May; 57(3):440-7. PubMed ID: 8169008
[TBL] [Abstract][Full Text] [Related]
38. In vitro induction of anterior gradient-2-specific cytotoxic T lymphocytes by dendritic cells transduced with recombinant adenoviruses as a potential therapy for colorectal cancer.
Lee HJ; Hong CY; Kim MH; Lee YK; Nguyen-Pham TN; Park BC; Yang DH; Chung IJ; Kim HJ; Lee JJ
Exp Mol Med; 2012 Jan; 44(1):60-7. PubMed ID: 22089087
[TBL] [Abstract][Full Text] [Related]
39. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
[TBL] [Abstract][Full Text] [Related]
40. Cell-surface markers for colon adenoma and adenocarcinoma.
Sewda K; Coppola D; Enkemann S; Yue B; Kim J; Lopez AS; Wojtkowiak JW; Stark VE; Morse B; Shibata D; Vignesh S; Morse DL
Oncotarget; 2016 Apr; 7(14):17773-89. PubMed ID: 26894861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
